ZnO Q-Dots Nanoparticles: Intensifying ROS Stress to Improve Anticancer Drug Efficacy
Open Access
- 25 August 2026
- journal article
- Published by Brieflands in International Journal of Cancer Management
- Vol. 19 (1) , e166395
Abstract
Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia that is effectively treated with arsenic trioxide (ATO) in combination with all-trans retinoic acid. However, the toxic effects of ATO necessitate exploring safer therapeutic combinations. Nanotechnology offers potential strategies to enhance drug efficacy and safety. Zinc oxide quantum dots (ZnO Q-dots) exhibit properties such as biocompatibility, selectivity, and the ability to induce reactive oxygen species (ROS), which may potentiate anticancer drug effects. Objectives: This study investigated the combined use of ZnO Q-dots and ATO to improve anticancer outcomes in NB4 APL-derived cells. Methods: NB4 cells were treated with varying concentrations of ZnO Q-dots and ATO, either alone or in combination. Cell viability was assessed using the trypan blue exclusion assay and the MTT assay. Proliferation was evaluated using the BrdU assay, and cell cycle distribution was analyzed by flow cytometry. Apoptosis- and autophagy-related markers were assessed using quantitative real-time PCR (qRT-PCR), and ROS levels were measured using a fluorogenic dye. Results: ZnO Q-dots enhanced the antiproliferative and apoptotic effects of ATO in a dose- and time-dependent manner. Combined treatment reduced metabolic activity to 39.7 ± 2.6%, corresponding to approximately 60.3% inhibition relative to controls. Significant upregulation of apoptotic genes (e.g., p53, Bax) and downregulation of anti-apoptotic genes (e.g., Bcl-2) were observed. ROS production was markedly increased, accompanied by induction of autophagy-related genes (ATG-7, Beclin-1). Conclusions: The combination of ZnO Q-dots and ATO enhances anticancer efficacy in APL-derived NB4 cells, primarily by increasing ROS production, apoptosis, and autophagy. These findings suggest a promising therapeutic strategy with improved efficacy compared with that of single-agent treatments.Keywords
This publication has 36 references indexed in Scilit:
- Multifunctional nanoparticle for cancer therapyMedcomm, 2023
- Interplay between oxidative stress, SIRT1, reproductive and metabolic functionsCurrent Research in Physiology, 2021
- ZnO Q-Dots-Induced Apoptosis Was Coupled with the Induction of PPARγ in Acute Promyelocytic Leukemia Cells; Proposing a Novel Application of Nanoparticles in Combination with PioglitazoneJournal of Cluster Science, 2021
- Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazoneThe International Journal of Biochemistry & Cell Biology, 2020
- Enhanced engineered ZnO nanostructures and their antibacterial activity against urinary, gastrointestinal, respiratory and dermal genital infectionsApplied Nanoscience, 2019
- Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to AprepitantThe International Journal of Biochemistry & Cell Biology, 2018
- Molecular‐targeted agents combination therapy for cancer: Developments and potentialsInternational Journal of Cancer, 2013
- Arsenic exposure in Latin America: Biomarkers, risk assessments and related health effectsScience of The Total Environment, 2012
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Specific SIRT1 Activation Mimics Low Energy Levels and Protects against Diet-Induced Metabolic Disorders by Enhancing Fat OxidationCell Metabolism, 2008